Publication & Citation Trends
Publications
0 total
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
Cited by 1
Semantic Scholar
The Urine Light Chain/eGFR Quotient as a Tool to Rule out Cast Nephropathy in Myeloma-Associated Kidney Failure OA
Cited by 0
Semantic Scholar
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Cited by 46
Semantic Scholar
Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase OA
Cited by 6
Semantic Scholar
Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial OA
Cited by 3
Semantic Scholar
Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia OA
Cited by 3
Semantic Scholar
Single Center Experience Using Monoclonal COVID-19 Antibodies in the Management of Immunocompromised Patients with COVID-19 OA
Cited by 2
Semantic Scholar
Research Topics
Acute Myeloid Leukemia Research
(156)
Chronic Myeloid Leukemia Treatments
(68)
Myeloproliferative Neoplasms: Diagnosis and Treatment
(46)
Chronic Lymphocytic Leukemia Research
(41)
Acute Lymphoblastic Leukemia research
(34)
Affiliations
Goethe University Frankfurt
University of Iowa
University of Maryland, Baltimore
Roswell Park Comprehensive Cancer Center
European Bioinformatics Institute